Comparing the effects of vasopressin and norepinephrine on renal function in patients undergoing CABG surgery

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20180724040575N9

Enrollment

Registered

2025-09-13

Start date

2025-09-23

Completion date

Unknown

Last updated

2025-09-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Patients undergoing CABG surgery. Chronic ischaemic heart disease, unspecified Ischaemic heart disease (chronic) NOS

Interventions

Intervention 1: First intervention group (receiving vasopressin): The product of EXIR Company under the trade name Hypress (containing 20 international units of vasopressin in one milliliter) will be

Eligibility

Sex/Gender

All

Age

40 Years to 80 Years

Inclusion criteria

Inclusion criteria: Patients who are candidates for CABG and taking ACE inhibitors and ARBs for at least 4 weeks CABG candidate patients with EF less than 40%

Exclusion criteria

Exclusion criteria: Renal failure Any contraindications to the use of vasopressin and norepinephrine Emergency surgery Off CPB surgery balloon pump insertion

Design outcomes

Primary

Measure	Time frame
Plasma cystatin C levels. Timepoint: Before surgery, when off the pump, and 6 hours after surgery. Method of measurement: Measurement by immunoassay method.;Plasma creatinine levels. Timepoint: Before surgery, when off the pump, and 6 hours after surgery. Method of measurement: Plasma level measurement by Jaffe reaction using alkaline picrate.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactKamal Fani

Shahid Beheshti University of Medical Sciences

kamalfani@sbmu.ac.ir+98 21 2207 4095

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026